NEWS & EVENTS

October, 2013

LIPOGEN has obtained provisional patent utilization license, and has a full right to further develop this application. Upon the completion of Phase I studies, BF175 will be further tested and characterized in higher mammals, as a part of the Phase II study, eventually leading to Clinical Trials and the commercialization of BF175 as a novel cancer treatment drug.

 

August 5th, 2013

LIPOGEN LLC has submitted Small Business Innovation Research (SBIR) grant application PA-13-234 to National Institute of Health, National Cancer Institute

"Small molecule based inhibition of cancer lipogenesis."

 

August 5th, 2013

LIPOGEN LLC has submitted Small Business Innovation Research (SBIR) grant application PA-13-234 to National Institute of Health, National Cancer Institute

"Identification of specific inhibitors and direct substrates of the oncoprotein CDK8"